Natco Pharma's Q2 FY 2026-27 Quarterly Results
- 14 Nov 2026
Result Summary
- Natco Pharma Ltd reported a 28.3% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Sep (Q2 FY 2026-27). On a year-on-year (YoY) basis, it witnessed a decline of 30.3%.
- Its expenses for the quarter were up by 27.5% QoQ and down 8.6% YoY.
- The net profit decreased 1.9% QoQ and decreased 60.9% YoY.
- The earnings per share (EPS) of Natco Pharma Ltd stood at 11.31 during Q2 FY 2026-27.
Financial Statments for Q2 FY 2026-27
(₹ crores) | Q2FY27 | Q1FY27 | Q2FY26 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 1019.40 | 794.40 | 1463.00 | 28.3% | -30.3% |
Total Expenses | 776.20 | 608.80 | 849.30 | 27.5% | -8.6% |
Profit Before Tax | 243.20 | 185.60 | 613.70 | 31.0% | -60.4% |
Tax | 69.80 | 63.40 | 95.80 | 10.1% | -27.1% |
Profit After Tax | 202.60 | 206.50 | 517.90 | -1.9% | -60.9% |
Earnings Per Share | 11.31 | 11.53 | 28.94 | -1.9% | -60.9% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Natco Pharma Ltd is a prominent player in the pharmaceutical industry known for its specialization in the production of generic drugs and active pharmaceutical ingredients (APIs). The company has a diverse portfolio that includes oncology, cardiology, neurology, and gastroenterology products. Natco Pharma has established its presence in both domestic and international markets, with a focus on delivering affordable medications. The company is committed to research and development to enhance its product offerings and maintain competitive advantage. As of the latest data, there are no specified recent major developments available.
Revenue
In the second quarter of the fiscal year 2027 (Q2FY27), Natco Pharma Ltd reported a total income of ₹1019.40 crores. This marks a quarter-over-quarter (QoQ) increase of 28.3% compared to the ₹794.40 crores recorded in the first quarter of fiscal year 2027 (Q1FY27). However, on a year-over-year (YoY) basis, there was a decline of 30.3% compared to the total income of ₹1463.00 crores in the second quarter of fiscal year 2026 (Q2FY26). These figures reflect significant changes in revenue performance over both the quarterly and yearly periods.
Profitability
The company's profit before tax (PBT) for Q2FY27 was ₹243.20 crores, demonstrating a QoQ increase of 31.0% from ₹185.60 crores in Q1FY27. However, this represents a YoY decline of 60.4% from ₹613.70 crores in Q2FY26. The tax expense for Q2FY27 was ₹69.80 crores, a 10.1% increase QoQ from ₹63.40 crores in Q1FY27, and a YoY decrease of 27.1% from ₹95.80 crores in Q2FY26. The profit after tax (PAT) for Q2FY27 was ₹202.60 crores, slightly decreasing by 1.9% QoQ from ₹206.50 crores in Q1FY27 and decreasing by 60.9% YoY from ₹517.90 crores in Q2FY26. The earnings per share (EPS) followed suit, reflecting similar QoQ and YoY changes as the PAT.
Operating Metrics
For the second quarter of fiscal year 2027, Natco Pharma Ltd's total expenses were reported at ₹776.20 crores, indicating a 27.5% QoQ increase from ₹608.80 crores in Q1FY27. On a YoY basis, total expenses decreased by 8.6% from ₹849.30 crores in Q2FY26. The changes in expenses over the quarterly and yearly periods are a key component of the company’s operating performance. The operating metrics indicate fluctuations in expenses relative to income, which impacts overall profitability.
FAQs
Natco Pharma Ltd announced its Q2 FY 2026-27 results on 14 November, 2026.
Natco Pharma Ltd quarterly results refer to the company’s financial performance over a three-month period, including key metrics like revenue, net profit, earnings per share (EPS), and margin performance.
Key highlights of Natco Pharma Ltd Q2 FY 2026-27 results include:
- Revenue: ₹1019.40 crore
- Net Profit: ₹202.60 crore
- EBITDA: ₹310.00 crore
- Year-over-Year Growth: -30.3%
- Quarter-over-Quarter Growth: 28.3%
Natco Pharma Ltd reported a net loss of ₹202.60 crore in Q2 FY 2026-27, reflecting a -60.9% year-over-year growth.
Natco Pharma Ltd posted a revenue of ₹1019.40 crore in Q2 FY 2026-27.